protein modeling and in-silico drug designing approach
TRANSCRIPT
![Page 1: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/1.jpg)
IN –SILICO DRUG IN –SILICO DRUG TARGET DESIGNING TARGET DESIGNING
FOR MIGRAINEFOR MIGRAINE
UNDER GUIDANCE OFUNDER GUIDANCE OF
Mr. ARVIND SINGH Mr. ARVIND SINGH FACULTY BII,NOIDA,INDIAFACULTY BII,NOIDA,INDIA
BY- BY- CHINMAYA MAHAPATRACHINMAYA MAHAPATRA
![Page 2: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/2.jpg)
INTRODUCTIONINTRODUCTION
• In-silico Drug Design
• In silico drug designing is defined as the identification of the drug target molecule by employing computational tools
![Page 3: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/3.jpg)
In silicoIn silico methods methods
• Identifying drug targets via bioinformatics tools.
• To analyze the target structures for possible binding/ active sites.
• Generating candidate molecules, checking for their drug likeness.
• Docking these molecules with the target• Ranking them according to their binding
affinites • Further lead optimization to improve binding
characteristics
![Page 4: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/4.jpg)
Steps in Drug DesigningSteps in Drug Designing
![Page 5: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/5.jpg)
MIGRAINEMIGRAINE• Migraine is a neurological disorder .A
migraine headache is a severe pain that is typically on one side of the head but sometimes on both sides.
• Migraines can occur at any time of the day and can last a few hours or up to one or two days.
• Migraine attacks can be very intense, forcing the sufferer to abandon normal daily activities.
• Migraine is commonly experienced between the ages of 15 and 55.
![Page 6: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/6.jpg)
SYMPTOMS OF MIGRAINESYMPTOMS OF MIGRAINE
• Intense pulsating or throbbing headache• Moderate to intense pain affecting daily activities• Nausea, vomiting or diarrhea• Increased sensitivity to smells• Increased sensitivity to sounds• Increased sensitivity to light (photophobia)• Visual disturbances or ‘aura’
![Page 7: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/7.jpg)
TYPES OF MIGRAINETYPES OF MIGRAINE
• Common Migraine (migraine without aura)
• Classical Migraine (migraine with aura)
• Opthalmoplegic migraine
• Hemiplegic migraine
• Basilar type migraine
• Abdominal migraine
• Acephalgic migraine
![Page 8: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/8.jpg)
PATHOPHYSIOLOGYPATHOPHYSIOLOGY
• Depolarization Theory.
• Vascular theory
• Serotonin theory
![Page 9: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/9.jpg)
![Page 10: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/10.jpg)
DRUGS PREVIOUSLY PRESCRIBED DRUGS PREVIOUSLY PRESCRIBED TO CURE MIGRAINETO CURE MIGRAINE
• Paracetamol - It is used to cure normal headaches but not effective in acute cases.
• Aspirin - Help relieve symtoms of nausea and help prevent vomiting. But effective only if taken early.
• Sumatriptan- Best drug available • Naproxen-Taken with caffiene• Ibuprofen-Generally taken with aspirin to be
effective• Ergotamine-Quite effective but has the side-
effect that it itself is very nauseated• Feverfew-Herbal medicine
![Page 11: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/11.jpg)
![Page 12: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/12.jpg)
DESCRIPTION OF PROCESS WITH SOFTWARES DESCRIPTION OF PROCESS WITH SOFTWARES
USEDUSED • TAKING A PROTEIN SEQUENCE FROM NCBI FOR
PROTEIN S(WHOSE DEFICIENCY CAUSES MIGRAINE).
• PROTEIN TAKEN IS BAF85683[Unnamed protein]. THEN PERFORMING ITS BLASTP.
• BLASTP (Basic Local Alignment Search Tool For Protein)
• Uses the BLAST algorithm to compare an amino acid query sequence against a protein sequence database.
![Page 13: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/13.jpg)
BLASTP RESULTSBLASTP RESULTS
![Page 14: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/14.jpg)
• Then taking a known protein similar in nature i.e. P98118(for RABBIT). And performing the comparative modelling through using GENO-3D.
• GENO-3D
• GENO-3D i.e. Homology Modeling involves taking a known sequence with an unknown structure and mapping it against a known structure of one or
several similar (homologous) proteins. • GENO-3D RESULTS
![Page 15: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/15.jpg)
![Page 16: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/16.jpg)
• SINCE THE MODEL 2 IS HAVING THE MAXIMUM SEQUENCE IDENTITY OF 87%. ITS RAMACHANDRAN PLOT IS DRAWN TO PREDICT THE RESIDUES AND THE STEREOCHEMISTRY OF THE UNKNOWN PROTEIN.
• RAMACHANDRAN PLOTS[USING PROCHECK SOFTWARE]
• A Ramachandran plot is a way to visualize dihedral angles φ against ψ of amino acid residues in protein structure. It shows the possible conformations of φ and ψ angles for a polypeptide.
![Page 17: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/17.jpg)
BETASHEET
ALPHALEFTHELIX
ALPHAHELIX
![Page 18: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/18.jpg)
• RAMACHANDRAN PLOT OF MODEL-2
COLOUR KEYGREEN-ALPHA REGIONBLUE-ADDITIONAL ALLOWED REGIONSRED-GENEROUSLY ALLOWED REGIONS
![Page 19: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/19.jpg)
• SINCE FURTHER INFORMATION ABOUT THE UNNAMED PROTEIN IS NOT AVAILABLE .THE SECOND APPROACH IS TAKEN BY CHOOSING A KNOWN PROTEIN INVOLVED IN MIGRAINE IN THE PDB(PROTEIN DATA BANK). The protein is 2YX8(Crystal structure of the extracellular domain of human RAMP1 ).
• DS VISUALISER• The structure of the protein is visualised through the DS VISUALIZER
![Page 20: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/20.jpg)
• SEQUENCE AS IN DS VISUALISER
![Page 21: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/21.jpg)
DESINING OF INHIBITOR(LIGAND) FOR THE DESINING OF INHIBITOR(LIGAND) FOR THE PROTEIN MOLECULEPROTEIN MOLECULE
• WHAT IS LIGAND?• Ligand is either an atom, ion, or molecule that bonds to a central metal,
generally involving formal donation of one or more of its electrons.
• DESINING OF LIGAND MOLECULE IN CHEMSKETCH
• CHEMSKETCH :-ACD/ChemSketch is an advanced chemical drawing tool for drawing different chemical structures.
• Five different drugs previously available were drawn along with their derivatives. The drugs are,
-Aspirin
-Ibuprofen
-Naproxen
-Paracetamol
-sumatriptan
![Page 22: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/22.jpg)
PROPERTIES OF THE DRUGS PROPERTIES OF THE DRUGS THAT WERE CACULATEDTHAT WERE CACULATED
• C log p:- partition (P) or distribution coefficient (D) is the ratio of concentrations of a compound in the two phases of a mixture of two immiscible solvents at equilibrium. Here ratio of (C octanol/C water) is taken.
• MOLECULAR WEIGHT• HYDROGEN BOND DONOR AND ACCEPTORS.• CHECKING FOR CALCULATING THE LIPINSKI 5’
RULES.• LIPINSKI 5’ RULES ARE –• Not more than 5 hydrogen bond donors• Not more than 10 hydrogen bond acceptors • A molecular weight under 500 g/mol • A partition coefficient log P less than 5
![Page 23: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/23.jpg)
TABLE CONTAINING LIGAND TABLE CONTAINING LIGAND WITH THEIR PROPERTIESWITH THEIR PROPERTIES
CH3
O
NH
OH
Molecular Form ula = C 8H 9NO 2
Form ula W eight = 151.16256Com position = C(63.56%) H(6.00%) N(9.27%) O(21.17%)Molar Refractiv ity = 42.40 ± 0.3 cm 3
Molar Volum e = 120.9 ± 3.0 cm 3
![Page 24: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/24.jpg)
FOR LIGAND DERIVATIVESFOR LIGAND DERIVATIVES
• D
![Page 25: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/25.jpg)
DOCKINGDOCKING
• Docking is a method which predicts the preferred orientation of one molecule to a second when bound to each other to form a stable complex. Knowledge of the preferred orientation in turn may be used to predict the strength of association or binding affinity between two molecules
![Page 26: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/26.jpg)
RESULTS OF DOCKINGRESULTS OF DOCKING• RESULT FOR DOCKING SHOWING SUMATRIPTAN DERIVATIVE GIVING
THE MINIMUM BINDING ENERGY VALUE.
![Page 27: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/27.jpg)
DRUGS,THEIR DERIVATIVES AND THEIR DRUGS,THEIR DERIVATIVES AND THEIR BINDING ENERGY VALUE[EVALUE]BINDING ENERGY VALUE[EVALUE]
ASPIRIN -136.47
ASPIRIN DERIVATIVES -128.96
IBUPROFEN -147.18
IBUPROFEN DERIVATIVES -155.34
NAPROXEN -156.39
NAPROXEN DERIVATIVES -161.20
PARACETAMOL -156.39
PARACETAMOL DERIVATIVES
-120.22
SUMATRIPTAN -162.74
SUMATRIPTAN DERIVATIVES -174.74
![Page 28: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/28.jpg)
RESULTS AND DISCUSSIONSRESULTS AND DISCUSSIONS
![Page 29: Protein Modeling And In-Silico Drug Designing Approach](https://reader035.vdocument.in/reader035/viewer/2022062703/5550121eb4c905af648b4993/html5/thumbnails/29.jpg)
REFERENCESREFERENCES• CLINICAL APPROACH TO HEADACHE IN CHILDREN AND PREVENTIVE
THERAPY OF MIGRAINE-KK SINHA(JIACM 2005;6(1):64-2).
• Migrainous Stroke in a Young Patient Associated with Protein S Deficiency- Sachin Kumar, Naresh Gupta, NP Singh, Sandeep Garg, Sameer Gulati(JIACM 2006;7(2):156-8)
• Recent advances in the diagnosis and management of migraine-Peter J Goadsby(Journal of medical biology 13May 2008).
• The Tight-Fit Brain - Study Reveals Brain Swelling As Cause of Migraine Headaches (New Research Unveiled at Physiological meeting at UCL-June 2006).
• Gene influencing migraine-ScienceDaily (Apr. 21, 2008) (American Journal of Human Genetics) .
• Protein may promote migraines-Andrew Russo-spring conference,2007 at the UI Carver College of Medicine,U.S.A